FdaApplication
BLA 761136
Identifiers
- fda_app_no: BLA761136
Properties
| Property | Value |
|---|---|
| applicant_name | Celgene Corporation, a Bristol-Myers Squibb Company |
| application_type | BLA |
| approval_date | 2019-11-08 |
Revenue by product
REBLOZYL
| Period | Revenue |
|---|---|
| Q2 2026 | $735.0M |
| Q1 2026 | $555.0M |
| Q4 2025 | $666.0M |
| Q3 2025 | $615.0M |
| Q2 2025 | $568.0M |
| Q1 2025 | $478.0M |
| Q4 2024 | $547.0M |
| Q3 2024 | $447.0M |
| Q2 2024 | $425.0M |
| Q1 2024 | $354.0M |
| Q4 2023 | $320.0M |
| Q3 2023 | $248.0M |
| Q2 2023 | $234.0M |
| Q1 2023 | $206.0M |
| Q4 2022 | $199.0M |
| Q3 2022 | $190.0M |
| Q2 2022 | $172.0M |
| Q1 2022 | $156.0M |
| Q4 2021 | $151.0M |
| Q3 2021 | $160.0M |
| Q2 2021 | $128.0M |
| Q1 2021 | $112.0M |
| Q4 2020 | $115.0M |
| Q3 2020 | $96.0M |
| Q2 2020 | $55.0M |
| Q1 2020 | $8.0M |
| Q4 2019 | $0.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
| Q1 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| REBLOZYL | LUSPATERCEPT-AAMT | 75MG/VIAL | For Injection |
| REBLOZYL | LUSPATERCEPT-AAMT | 25MG/VIAL | For Injection |
2 products